Melinta Therapeutics Announces Positive Top-Line Results in Phase III Trial of Baxdela® (delafloxacin) for Treatment of CABP

Stock Information for Melinta Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.